CO2017000558A2 - Variantes de proteínas de unión al factor h - Google Patents

Variantes de proteínas de unión al factor h

Info

Publication number
CO2017000558A2
CO2017000558A2 CONC2017/0000558A CO2017000558A CO2017000558A2 CO 2017000558 A2 CO2017000558 A2 CO 2017000558A2 CO 2017000558 A CO2017000558 A CO 2017000558A CO 2017000558 A2 CO2017000558 A2 CO 2017000558A2
Authority
CO
Colombia
Prior art keywords
binding proteins
variants
factor binding
proteins
strain
Prior art date
Application number
CONC2017/0000558A
Other languages
English (en)
Spanish (es)
Inventor
Peter T Beernink
Original Assignee
Childrens Hospital & Res Center At Oakland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital & Res Center At Oakland filed Critical Childrens Hospital & Res Center At Oakland
Publication of CO2017000558A2 publication Critical patent/CO2017000558A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2017/0000558A 2014-07-23 2017-01-23 Variantes de proteínas de unión al factor h CO2017000558A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462028123P 2014-07-23 2014-07-23
PCT/US2015/041616 WO2016014719A1 (en) 2014-07-23 2015-07-22 Factor h binding protein variants and methods of use thereof

Publications (1)

Publication Number Publication Date
CO2017000558A2 true CO2017000558A2 (es) 2017-06-20

Family

ID=55163727

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0000558A CO2017000558A2 (es) 2014-07-23 2017-01-23 Variantes de proteínas de unión al factor h

Country Status (15)

Country Link
US (10) US10266572B2 (cg-RX-API-DMAC10.html)
EP (2) EP4074726A3 (cg-RX-API-DMAC10.html)
JP (4) JP6796057B2 (cg-RX-API-DMAC10.html)
KR (2) KR102752259B1 (cg-RX-API-DMAC10.html)
CN (3) CN112851768A (cg-RX-API-DMAC10.html)
AU (5) AU2015292615B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017001417B1 (cg-RX-API-DMAC10.html)
CA (2) CA3212723A1 (cg-RX-API-DMAC10.html)
CO (1) CO2017000558A2 (cg-RX-API-DMAC10.html)
CR (1) CR20170020A (cg-RX-API-DMAC10.html)
ES (1) ES2922554T3 (cg-RX-API-DMAC10.html)
MX (3) MX382409B (cg-RX-API-DMAC10.html)
NZ (2) NZ766005A (cg-RX-API-DMAC10.html)
RU (1) RU2714248C2 (cg-RX-API-DMAC10.html)
WO (1) WO2016014719A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201802933T4 (tr) 2010-03-30 2018-03-21 Childrens Hospital & Res Center At Oakland Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi.
BR112017001417B1 (pt) 2014-07-23 2023-11-07 Children's Hospital & Research Center At Oakland Variantes da proteína de ligação ao fator h (fhbp), composição imunogênica e uso de uma fhbp variante referência cruzada
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
KR101855133B1 (ko) 2016-11-16 2018-05-08 주식회사 케이엠더블유 적층구조의 mimo 안테나 어셈블리
WO2018093176A2 (ko) 2016-11-16 2018-05-24 주식회사 케이엠더블유 적층구조의 mimo 안테나 어셈블리
KR102822764B1 (ko) * 2017-12-04 2025-06-19 인트라백 비.브이. 외막 소포의 생성을 위한 개선된 방법
EP3607967A1 (en) * 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
GB202016604D0 (en) 2020-10-20 2020-12-02 Univ Of Oxford Compositions and methods for inducing an immune response
TW202245836A (zh) 2021-02-19 2022-12-01 美商賽諾菲巴斯德公司 重組b型腦膜炎球菌疫苗
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物
WO2026072910A1 (en) 2024-09-27 2026-04-02 Sanofi Pasteur Inc. Anti-meningococcal antibodies for in vitro immunoassay

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
BR9909915A (pt) 1998-04-09 2000-12-26 Smithkline Beecham Biolog Composições adjuvantes
US20070026021A1 (en) 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
MX343752B (es) 1998-05-01 2016-11-22 Novartis Vaccines & Diagnostics Inc Antigenos de neisseria meningitidis y composiciones que los contienen.
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
ES2284287T3 (es) 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
CA2366152A1 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
IL148671A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
HK1049106A1 (zh) 1999-09-24 2003-05-02 Smithkline Beecham Biologicals S.A. 聚氧化乙烯山梨糖酯和octooxynol的聯用做為佐劑和其在疫苗中的用途
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
AU2013206190A1 (en) 1999-11-29 2013-06-27 Novartis Vaccines And Diagnostics S.R.L. Compositions comprising Neisseria meningitidis antigens from serogroups B and C as well as a further antigen
ES2588917T3 (es) 2000-01-17 2016-11-07 Glaxosmithkline Biologicals Sa Vacuna de VME suplementada contra meningococo
PT2270030E (pt) 2000-02-28 2012-07-24 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
US6839862B2 (en) 2001-05-31 2005-01-04 Koninklijke Philips Electronics N.V. Parallel data communication having skew intolerant data groups
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
EP2351579B1 (en) 2002-10-11 2016-09-21 Novartis Vaccines and Diagnostics S.r.l. Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
WO2004074433A2 (en) 2003-01-30 2004-09-02 Yale University Rag polypeptides, nucleic acids, and their use
US7628995B2 (en) * 2003-12-23 2009-12-08 Glaxosmithkline Biologicals S.A. Outer membrane vesicles and uses thereof
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
CN101107007B (zh) 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
ZA200707420B (en) 2005-02-14 2009-04-29 Univ Iowa Res Found Methods and reagents for treatment and diagnosis of age-related macular degeneration
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
WO2009038889A1 (en) 2007-08-02 2009-03-26 Children's Hospital And Research Center At Oakland Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
AU2009215364B2 (en) * 2008-02-21 2014-09-18 Glaxosmithkline Biologicals S.A. Meningococcal fHBP polypeptides
AU2009223613B2 (en) * 2008-03-10 2014-09-25 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
US8476032B2 (en) 2008-08-27 2013-07-02 Children's Hospital & Research Center Oakland Complement factor H-based assays for serum bactericidal activity against Neisseria meningitidis
WO2010028096A2 (en) 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of an a domain of factor h binding protein and methods of use
IT1394288B1 (it) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition
CN104548082A (zh) 2009-03-24 2015-04-29 诺华股份有限公司 为脑膜炎球菌因子h结合蛋白添加佐剂
US9266942B2 (en) 2009-04-30 2016-02-23 Children's Hospital & Research Center Oakland Chimeric factor H binding proteins (fHbp) and methods of use
CA2779816A1 (en) * 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
TR201802933T4 (tr) * 2010-03-30 2018-03-21 Childrens Hospital & Res Center At Oakland Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi.
KR101584871B1 (ko) * 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
CN102028941B (zh) 2011-02-11 2013-02-13 中国医学科学院医学生物学研究所 一种b群脑膜炎球菌重组蛋白嵌合疫苗及其制备方法
EP2729167B1 (en) 2011-07-07 2018-03-14 De Staat der Nederlanden, vert. door de Minister van VWS A process for detergent-free production of outer membrane vesicles of a gram-negative bacterium
WO2013078223A1 (en) 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
CA2865745C (en) * 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
GB201215005D0 (en) 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
WO2015017817A1 (en) * 2013-08-02 2015-02-05 Children's Hospital & Research Center Oakland Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof
CN106661092B (zh) 2014-02-28 2021-07-06 葛兰素史密丝克莱恩生物有限公司 修饰的脑膜炎球菌fHbp多肽
KR20150128099A (ko) 2014-05-08 2015-11-18 (주)엘지하우시스 Pla 및 pha 혼합수지를 이용한 벽지 및 그 제조 방법
CN107349423B (zh) * 2014-06-24 2021-03-19 上海生物制品研究所有限责任公司 一种脑膜炎球菌抗原组合及其应用
MX2017000776A (es) * 2014-07-17 2017-05-04 Glaxosmithkline Biologicals Sa Polipeptidos fhbp meningococicos modificados.
BR112017001417B1 (pt) 2014-07-23 2023-11-07 Children's Hospital & Research Center At Oakland Variantes da proteína de ligação ao fator h (fhbp), composição imunogênica e uso de uma fhbp variante referência cruzada
EP3607967A1 (en) * 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides

Also Published As

Publication number Publication date
AU2025202774A1 (en) 2025-05-08
US20170183384A1 (en) 2017-06-29
US10836799B2 (en) 2020-11-17
US10995122B2 (en) 2021-05-04
MX2023000204A (es) 2023-02-09
CA2955802A1 (en) 2016-01-28
JP2021000121A (ja) 2021-01-07
MX2021005373A (es) 2021-07-06
US20240025951A1 (en) 2024-01-25
US10266572B2 (en) 2019-04-23
EP4074726A3 (en) 2022-11-23
US11673920B2 (en) 2023-06-13
CN106715464B (zh) 2021-03-16
US12129282B2 (en) 2024-10-29
US20210101942A1 (en) 2021-04-08
JP2023011916A (ja) 2023-01-24
RU2017104742A3 (cg-RX-API-DMAC10.html) 2019-02-27
JP2025108722A (ja) 2025-07-23
AU2021203828B2 (en) 2023-04-13
US20190225655A1 (en) 2019-07-25
US20250136648A1 (en) 2025-05-01
KR102761870B1 (ko) 2025-02-05
CR20170020A (es) 2017-08-10
US10487122B2 (en) 2019-11-26
AU2019264600A1 (en) 2019-12-05
NZ766003A (en) 2024-01-26
EP4074726A2 (en) 2022-10-19
RU2017104742A (ru) 2018-08-29
EP3172224A4 (en) 2018-04-18
AU2019264600B2 (en) 2021-04-01
NZ766005A (en) 2024-03-22
KR20170028442A (ko) 2017-03-13
EP3172224B1 (en) 2022-06-29
KR102752259B1 (ko) 2025-01-13
AU2021203828A1 (en) 2021-07-08
US20200095288A1 (en) 2020-03-26
AU2023204391B2 (en) 2025-01-23
CN112851768A (zh) 2021-05-28
AU2023204391A1 (en) 2023-08-03
US12269849B2 (en) 2025-04-08
AU2025202774A9 (en) 2026-03-05
CA3212723A1 (en) 2016-01-28
US20250154206A1 (en) 2025-05-15
ES2922554T3 (es) 2022-09-16
AU2015292615A1 (en) 2017-03-16
RU2714248C2 (ru) 2020-02-13
NZ729206A (en) 2022-07-01
AU2015292615B2 (en) 2019-10-24
EP3172224A1 (en) 2017-05-31
JP7719046B2 (ja) 2025-08-05
US11834476B2 (en) 2023-12-05
JP2017522877A (ja) 2017-08-17
KR20230155595A (ko) 2023-11-10
CA2955802C (en) 2023-10-31
BR112017001417A2 (pt) 2017-11-21
JP6796057B2 (ja) 2020-12-02
MX382409B (es) 2025-03-13
US20200109179A1 (en) 2020-04-09
CN106715464A (zh) 2017-05-24
JP7221917B2 (ja) 2023-02-14
MX2017001038A (es) 2018-02-09
RU2020105192A (ru) 2020-02-12
CN119613509A (zh) 2025-03-14
BR112017001417B1 (pt) 2023-11-07
WO2016014719A1 (en) 2016-01-28
NZ766444A (en) 2024-01-26
US20210340191A1 (en) 2021-11-04
US20240101610A1 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
CR20170020A (es) Variantes de proteínas de unión al factor h y métodos de uso de estas
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
SA519402159B1 (ar) بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
MX391159B (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
MX2017014136A (es) Anticuerpos anti-cd166, anticuerpos anti-cd166 activables, y metodos de uso de los mismos.
MX2018016078A (es) Composiciones que comprenden cepas bacterianas.
MX2018015853A (es) Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137).
EA201890945A1 (ru) Биологические препараты и их применение в отношении растений
BR112017001579A2 (pt) anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
BR112017011932A2 (pt) ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso?
MX383464B (es) Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
MX2015013181A (es) Anticuerpos humanos pac1.
EA201790294A1 (ru) Средства на основе флагеллина и применения, включающие эффективную вакцинацию
EA201691363A1 (ru) Стабилизированные силикатные композиции и их применение в качестве антиперспирантных композиций
UY35718A (es) Anticuerpos anti-csf-1r: métodos de expresión de los mismos.
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
CL2015001772A1 (es) Composición farmacéutica para el tratamiento de dolor cabeza, y método de preparación de la misma.
EA201890149A1 (ru) Композиции криопреципитатов и способы их получения
EA201692554A1 (ru) Менингококковые вакцины
EA201791716A1 (ru) Фармацевтический состав
MX389103B (es) Anticuerpos contra ticagrelor y métodos de uso.
EA201691493A1 (ru) Замещенные n-арилпиридиноны